Cibus, Inc.

As of September 3, 2025, Cibus, Inc. is in a bearish trend, indicated by negative signals from moving averages and Bollinger Bands, and has underperformed the S&P 500 with a year-to-date return of -51.44% compared to the S&P's 12.22%.

As of March 21, 2024, Cibus, Inc. is rated as risky due to significant financial deterioration, overvaluation indicated by a negative P/E ratio and poor returns compared to peers and the S&P 500, with a year-to-date decline of -51.44% and a five-year drop of -99.58%.

As of March 21, 2024, Cibus, Inc. is considered overvalued and "risky" due to troubling financial metrics, including a price-to-book value of 0.81, an EV to EBITDA ratio of -3.40, a return on equity of -132.88%, and a one-year stock return of -84.90%, significantly underperforming the S&P 500's 10.26%.

As of June 2, 2025, Cibus, Inc. shows a mildly bearish trend due to bearish daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the MACD, indicating overall weakness and underperformance compared to the S&P 500.

As of March 2022, the management team of Cibus, Inc. includes Dr. Yves Ribeill (Chairman), Mr. James Blome (CEO), and several independent directors: Mr. Philippe Dumont, Mr. Jonathan Fassberg, Ms. Anna Kozicz-Stankiewicz, and Ms. Kimberly Nelson. They oversee the company's strategic direction and operations.

Cibus, Inc. is a micro-cap food and agriculture company that specializes in healthier specialty food ingredients and crop traits. As of March 2025, it reported net sales of $1 million and a net loss of $49 million, with a market cap of $72.71 million.

As of Jun 18, Cibus, Inc. has a market capitalization of 72.71 million, with net sales of 4.75 million and a net profit of -305.13 million over the last four quarters. The company reported shareholder's funds of 92.16 million and total assets of 350.07 million as of Dec 24.